The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance

Abstract

Vascular endothelial growth factor (VEGF) has become a major target in cancer treatment as it promotes tumor angiogenesis. Therapy with anti-VEGF antibody bevacizumab reportedly induces high levels of circulating VEGF which may potentially contribute to resistance. Based on animal or computational models, mechanisms of VEGF induction by bevacizumab have… (More)
DOI: 10.18632/oncotarget.11084

Topics

9 Figures and Tables

Cite this paper

@inproceedings{Alidzanovic2016TheVR, title={The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance}, author={Lejla Alidzanovic and Patrick Starlinger and Dominic Schauer and Thomas Maier and Alexandra Feldman and Elisabeth Buchberger and Judith Stift and Ulrike Koeck and Lorand Pop and Birgit Gruenberger and Thomas Gruenberger and Christine Brostjan}, booktitle={Oncotarget}, year={2016} }